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Pulmonary Resection for Metastatic Gastric Cancer
Clinton D. Kemp, MD,* Mio Kitano, MD,* Sid Kerkar, MD,* R. Taylor Ripley, MD,*
Jens U. Marquardt, MD,† David S. Schrump, MD,* and Itzhak Avital, MD*
Introduction: Sixteen percent of patients with gastric cancer will
develop pulmonary metastases. Standard of care for these patients is
systemic chemotherapy with a median survival of 6 months and a
5-year survival of only 2%. Our aim was to critically evaluate the
published data on pulmonary resection for metastatic gastric cancer
(MGC) and to analyze the potential rationale for surgical manage-
ment to determine which patients may benefit from this approach.
Methods: The Pubmed and SCOPUS databases were queried for all
studies reporting on pulmonary resections for MGC. All available
clinicopathologic data were analyzed.
Results: Twenty-one studies from 1975 to 2008 reported 48 pul-
monary resections in 43 patients including five repeat resections and
four extrapulmonary metastasectomies. Eighty-two percent (34/43)
of patients had solitary lesions with a median size of 24 mm (4–90
mm). Median time from gastrectomy to pulmonary resection was 35
months (0–120 months). At a median follow-up of 23 months, 15 of
43 (35%) patients were alive without disease, and two patients died
without disease. Median survival was 29 months (3–84 months)
after pulmonary metastasectomy and 65 months (5–180 months)
after gastrectomy. Fifty-six percent (24/43) of patients had another
recurrence at a median of 12 months (range: 6–48 months) after
resection including 30% (13/43) of patients with pulmonary recurren-
ces. Overall 5-year survival was 33%.
Conclusions: Pulmonary metastasectomy for MGC can potentially
result in long-term survival in a highly selected group of patients and
should be considered for those who present with small, isolated
lesions after a prolonged disease-free interval.
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Cancer is the second leading cause of death in the UnitedStates. Although the incidence and mortality of gastric
cancer has decreased significantly since the 1930s, this ma-
lignancy is still the fourth most common cancer worldwide
and the 14th most common in the United States.1 In 2009,
there will be an estimated 21,130 new cases diagnosed (1.5%
of all new cancers) and approximately 10,620 deaths (5.2% of
all cancer deaths) from gastric cancer in the United States.1,2
The lifetime risk for development of gastric cancer is approx-
imately 1 in 113 with an age-adjusted incidence of 8 in
100,000 and annual death rate of 4.1 per 100,000.3 The
overall 5-year survival is 24.7%, ranging from 78% for
localized disease to 2% for distant disease.4 Unfortunately, at
diagnosis, only 25% of patients present with localized disease
confined to the stomach itself; 30% present with regional
nodal disease, and another 35% have distant metastases at
presentation.5
Among patients who present with localized disease and
undergo R0 resections, almost half will experience a recur-
rence. A recent retrospective review of 1172 patients who
underwent R0 resections of gastric tumors with curative
intent demonstrated a recurrence rate of 42%; 79% occurred
in the first 2 years after gastric resection and rarely occurred
after 4 years.6 More than half of patients with recurrences
developed distant disease including 16% of patients who
developed pulmonary metastases. Data from autopsy series of
patients with gastric cancer demonstrate pulmonary metasta-
ses in 22 to 52% of patients.6,7 The incidence of clinically
apparent pulmonary metastases ranges from 0.5 to 16%, and
0.3 to 6% of patients will have isolated pulmonary metastases
from gastric cancer.6,8,9
Life expectancy from the time of pulmonary recurrence
is poor with a median survival of 6 months, which is not
significantly affected by systemic chemotherapy.10 Seventy
percent of patients are dead within 1 year, and 89% are dead
within 2 years of recurrence.6 A meta-analysis of patients
with metastatic gastric cancer (MGC) demonstrated a 5-year
survival of 0 to 7% with an overall 5-year survival of 2% with
chemotherapy alone.11 No patients with pulmonary metasta-
ses treated with chemotherapy alone survived to the 5-year
follow-up in any of these trials.
Once considered the sine qua non for surgically unre-
sectable disease, advances in anesthesia, thoracic surgery,
and postoperative care have made pulmonary metastasecto-
mies for other intestinal malignancies such as colorectal
cancer an essential part of the treatment of metastatic disease.
A review of more than 5000 patients who underwent pulmo-
nary resections for malignancies of various histologies
showed that after complete metastasectomy, a median sur-
vival of 35 months with long-term survival of 36% at 5 years,
26% at 10 years, and 22% at 15 years is possible in selected
patients and histologies.12
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Pulmonary metastasectomy for metastatic colorectal
cancer has become standard of care based on retrospective
data alone and has never been subjected to a randomized
controlled trial. Thus far, there have been no comprehensive
analyses of the published data describing pulmonary metas-
tasectomies for MGC. Furthermore, no studies comparing
surgical resection to best alternative care of systemic chemo-
therapy have addressed this topic in a prospective randomized
fashion.
It was our goal to review all published data for pulmo-
nary resection of MGC and to attempt to identify potential
patients who might benefit from this treatment modality.
MATERIALS AND METHODS
A comprehensive search of the Medline and SCOPUS
databases was performed to identify all published reports of
pulmonary resections for gastric cancer in three languages
(English, German, and Japanese) using the following key-
words: lung, pulmonary, metastasis, gastric, stomach, cancer,
resection, and metastasectomy. All non-English publications
were translated by an author fluent in the primary language of
the publication. Data collected included the year of publica-
tion, name and country of institution, size of the series,
patient demographics, pathologic details of primary gastric
tumors including American Joint Committee on Cancer tu-
mor, node, metastasis staging, site of first recurrence, timing
of pulmonary metastasis and resection, type of operation,
pathologic details of metastatic tumor, time to recurrence
from metastasectomy, adjuvant and neoadjuvant chemother-
apy and radiation therapy, follow-up, and overall survival
(OS). Kaplan-Meier curves were generated for disease-free
survival (DFS) and OS after gastrectomy and pulmonary
metastasectomy using SigmaPlot software (Systat Software,
San Jose, CA). Demographic and clinicopathological factors
were used to generate separate Kaplan-Meier curves, and
these were then evaluated for their association with DFS and
OS. Statistical differences between curves were calculated by
using the log-rank test. All p values are presented as two
tailed without adjustment for multiple comparisons, and p
values less than 0.05 were considered significant.
RESULTS
Patients
Twenty-one publications from 1975 to 2008 from 201
institutions in two countries were identified (Table 1).7–9,13–30
The majority of studies, 57% (12/21), were single case
reports. These studies reported on 43 patients who underwent
48 pulmonary metastasectomies for MGC, including five
patients who underwent repeat pulmonary resection. The
median age of patients was 67 years (range: 42–84 years),
and the majority (83%) were men. Most patients, 95% (41/
43), were treated in Japan, and the other 5% (2/44) were
treated in Germany.
Clinicopathologic Features of Primary Gastric
Tumors
All patients had histopathologically confirmed met-
astatic gastric adenocarcinoma (Table 2). Staging data of
the primary gastric tumors were available for 34 patients
(79%) and included 38% (13/34) with stage I tumors (one
unspecified, three IA, and nine IB), 15% (5/34) with stage
II tumors, 32% (11/34) with stage III tumors (seven IIIA
and four IIIB), and 15% (5/34) with stage IV tumors (four
T4 tumors and one M1).
Fifteen percent (5/34) of patients had T1 tumors, 47%
(16/34) had T2 tumors, 23% (8/34) had T3 tumors, and 15%
(5/34) had T4 tumors. Thirty-five percent (12/34) of the
patients had N0 disease, 38% (13/34) had N1 disease, 15%
(5/34) had N2 disease, and 12% (4/34) had N3 disease.
Six tumors had evidence of lymphatic and/or vascular
invasion on final pathology. For those with histologic de-
scriptions, 53% (8/15) of tumors were well differentiated,
33% (5/15) were moderately differentiated, and 13% (2/15)
were reported as poorly differentiated.
Data on the extent of gastric resections were available
for 86% (37/43) of the patients. Sixty-two percent (23/37) of
the patients underwent total gastrectomy, and 38% (14/37) of
the patients underwent distal gastrectomy. Extent of lymph
node dissection was not reported in any study. All patients
were resected to no evidence of disease after gastrectomy.
Data on neoadjuvant treatment before gastrectomy were
available for 50% (22/44) of patients, none of whom received
neoadjuvant chemotherapy or radiation before primary gas-
trectomy. Data on adjuvant therapy after gastrectomy were
available for 65% (28/43) of the patients, 36% (10/28) of
whom received adjuvant chemotherapy and one of whom also
received adjuvant radiation therapy.
Prognostic Factors at Gastrectomy
Demographic and clinicopathologic factors were exam-
ined to determine any prognostic factors associated with DFS
after gastrectomy (Table 3). There was a trend toward de-
creased DFS among patients with more advanced stage tu-
mors (T3–4) compared with those with less advanced tumors
(T1–2) (median DFS 24 months versus 34 months, p 
0.194); however, the only factor found to be statistically
significant was type of gastrectomy with those patients un-
dergoing distal gastrectomies having longer DFS than those
undergoing total gastrectomy (42 months versus 24 months,
p  0.02). On further analysis, those patients who underwent
total gastrectomy were found to have higher overall stage
tumors than those who underwent distal gastrectomy. Patients
in the total gastrectomy group had 24% and 76% stage I and
stages II–IV tumors, respectively, compared with 62% and
38% among those undergoing distal gastrectomy. Similarly,
T and N stages were higher among patients in the total
gastrectomy group with 52% T1–2 and 48% T3–4 lesions
with 19% N0 and 81% N1–3 tumors compared with 77%
T1–2 and 23% T3–4 lesions with 62% N0 and 38% N1–3
tumors in the distal gastrectomy group. The association of
adjuvant chemotherapy after gastrectomy on DFS was also
examined, and there was no statistically significant differ-
ence in DFS between those who received adjuvant chemo-
therapy and those who did not (22 months versus 39
months, p  0.139).
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Timing of Pulmonary Metastases
Ninety-eight (42/43) percent of patients presented with
metachronous pulmonary metastases and 2% (1/43) had a
synchronous presentation. Of the patients presenting with
metachronous pulmonary MGC, the majority of patients,
95% (40/42), had a pulmonary metastasis as the first site of
metastatic disease. The median disease-free interval (DFI)
was 35 months (0–108 months). Seven percent (3/43) had
hepatic metastases before pulmonary metastases. The DFI
before hepatic metastasis was 14 and 38 months in the two
patients in which this data were available. Fifty-one percent
(22/43) of patients had detailed information regarding the
diagnosis of pulmonary metastases. All these patients had
radiographic evidence of metastasis (chest x-ray or computed
tomography) during routine follow-up, and two patients also
had subsequent bronchoscopy. No tumors were pathologi-
cally confirmed to be MGC before resection. Twenty-three
percent (5/22) of tumors were associated with abnormal
TABLE 1. Studies Reporting Pulmonary Resections for Gastric Cancer
Study Author Institution Year Patients Follow-Up (mo) Status
1 Siono et al.13 Tokushima University 1975 1 12 Alive
2 Mai et al.14 Kanazawa University 1984 1 NR Alive
3 Tomita et al.15 Nagasaki University 1988 1 9 Dead
4 Raute and Trede16 1989 1 NR NR
5 Umehara et al.8 Hamamatsu University 1989 2 79 Alive
65 Dead
6 Konno et al.17 Hamatsu University 1995 1 48 Alive
7 Piltz et al.18 1996 1 8 Dead
8 Urabe et al.7 Juntendo University 1996 2 42 Dead
39 Alive
9 Kamiyoshihara et al.19 Gunma University 1998 3 NR Dead
Dead
Dead
10 Kanemitsu et al.9 National Cancer Center 1998 4 23 Dead
45 Dead
10 Dead
19 Dead
11 Tsumatori et al.20 National Defense Medical College 1998 5 60 Alive
Dead
Dead
Dead
Dead
12 Tanaka et al.21 Yamaguchi University 2000 1 23 Alive
13 Kobayashi et al.22 Kanagawa Cencer center 2001 1 NR NR
14 Tamura et al.23 National Kinki-Chuo Hospital 2002 4 12 Dead
19 Dead
6 Dead
18 Dead
15 Inoue et al.24 Osaka Prefectural General Hospital 2002 1 180 Alive
16 Nakahashi et al.25 National Cancer Center East 2004 1 60 Alive
17 Tsuboshima et al.26 Shimane University 2006 1 8 NR
18 Takahiro et al.27 Miyagi Cancer Center 2006 2 26 Alive
21 Alive
19 Sakaguchi et al.28 Tokyo Metropolitan Komagome Hospital 2007 7 3 Dead
59 Dead
76 Alive
21 Alive
21 Alive
33 Alive
8 Alive
20 Mikami et al.29 Fukuoka University 2007 2 10.2 Dead
10.2 Dead
21 Nakayama et al.30 Kanagawa Cancer Center 2008 1 65 Dead
NR, not reported.
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laboratory values (three with elevated CEA and two with
elevated AFP). Fourteen percent (3/22) of patients were
symptomatic with cough or fever.
Of the 74% (32/43) of the patients for whom the
preoperative workup for pulmonary metastases was de-
scribed, 47% (15/32) of patients were thought to have MGC,
31% (10/32) of patients were thought to have primary lung
cancer, and 22% (7/32) of the patients were thought to have
either primary lung cancer or gastric metastases before resec-
tion. Therefore, the preoperative intent was to perform a
metastasectomy in approximately half of the patients,
whereas the remainder had incidentally discovered gastric
cancer on pathologic examination.
Clinicopathologic Features of Resected
Pulmonary Metastases
Eighteen studies reported details about the 48 pulmo-
nary resections in the 43 patients included in our analysis
(Table 4). Overall, pulmonary resections were performed at a
median of 35 months (range: 0–120 months) after primary
gastrectomy in the 19 studies for which information was
available. Of the 88% (42/48) of the pulmonary resections for
which detailed data were available, the majority of patients
81% (34/42) had one lesion, 17% (7/42) had two lesions, and
2% (1/42) had three lesions resected in the same operation.
Lesion size was reported in 44% (22/48) of resections. The
median size of the resected MGC in the lung was 24 mm
(range: 4–90 mm). All patients were resected to no evidence
of disease after pulmonary metastasectomy.
Seventeen right-sided resections, eight left-sided resec-
tions, and 23 nonspecified resections were performed. All the
patients who had more than one lesion resected had disease
that was confined to one hemithorax. For the seven patients
with two lesions resected, five patients had unilobar ipsilat-
eral disease, and two patients had disease in two lobes. The
one patient with three lesions had disease in two lobes.
Of the pulmonary resections performed, 44% (21/48),
21% (10/48), 8% (4/48), 2% (1/48), and 2% (1/48) were
TABLE 2. Clinicopathological Features of Primary Gastric
Tumors
n Percentage
Stage (n  34), overall
I 13 38
II 5 15
III 11 32
IV 5 15
T
1 5 15
2 16 47
3 8 24
4 5 15
N
0 12 35
1 13 38
2 5 15
3 4 12
M
0 33 97
1 1 3
Gastrectomy (n  37)
Total 23 62
Distal 14 38
Neoadjuvant therapy (n  22)
Chemotherapy 0 0
Radiation therapy 0 0
Adjuvant therapy (n  28)
Chemotherapy 10 36
Radiation therapy 1 4
TABLE 3. Prognostic Factors for Disease-Free Survival After
Gastrectomy
Feature Group Patients
Median
DFS (mo) p
Sex Male 6 20 0.791
Female 24 38
Age 66.5 yr 15 33 0.186
66.5 yr 16 45
Overall stage I and II 16 34 0.194
III and IV 13 24
T stage T1–2 19 33 0.495
T3–4 10 38
N stage N0 10 33 0.261
N1–3 19 34
Gastrectomy Distal gastrectomy 12 42 0.02
Total gastrectomy 20 24
DFS, disease-free survival
TABLE 4. Clinicopathological Features of the Pulmonary
Metastases
n Percentage
Number of lesions (n  42)
1 34 81
2 7 17
3 1 2
Location of lesion (n  28)
RUL 11 39
RML 3 11
RLL 5 18
LUL 4 14
LLL 5 18
Type of resection (n  38)
Pneumonectomy 0
Lobectomy 21
Segmentectomy 10
Wedge 5
Other 2
Adjuvant therapy (n  27)
Chemotherapy 7 26
Radiation therapy 0 0
Median (mm) Range (mm)
Size of lesion (n  22) 24 4–90
Journal of Thoracic Oncology • Volume 5, Number 11, November 2010 Pulmonary Resection for Gastric Cancer
Copyright © 2010 by the International Association for the Study of Lung Cancer 1799
lobectomies, segmentectomies, wedge resections, combined
lobectomy and wedge resection, and sternal resection with en
bloc wedge resection, respectively. Ten percent (5/48) were
pulmonary resections that were not otherwise specified. The
extent of thoracic lymphadenectomy was not reported in any
study; however, 10 studies reported lymph node status on
final pathology, and two of these patients had evidence of
lymphatic involvement. Operative complications were re-
ported in 10 studies; in nine, there were no morbidities
reported, and in one there was a chylothorax. There were no
perioperative mortalities.
Data on adjuvant chemotherapy or radiation therapy
after pulmonary resection were reported for 63% (27/43) of
the patients, 26% (7/27) of whom received chemotherapy,
and none of whom received radiation therapy to the chest
after their pulmonary resections. Five percent (2/43) of the
patients subsequently underwent radiation therapy for intra-
cranial metastases, which developed after pulmonary resec-
tion. Adjuvant chemotherapy after pulmonary metastasec-
tomy was not associated with a statistically significant
difference in DFS (median DFS: 36 months versus not yet
reached, p  0.561) or OS (median OS: 39 months versus 21
months p  0.707) compared with no chemotherapy.
Prognostic Factors at Pulmonary
Metastasectomy
Demographic and clinicopathological data were ana-
lyzed to evaluate for prognostic factors for DFS and OS after
pulmonary metastasectomy (Tables 5 and 6). There were no
statistically significant prognostic factors for DFS after pul-
monary metastasectomy. There were no statistically signifi-
cant prognostic factors for OS; however, there was a trend
toward increased OS among patients who had longer than the
historical DFI of 24 months (median OS: 65 months versus
19 months, p  0.119) and who had less extensive resections
compared with lobectomy (median OS: not reached versus 45
months, p  0.081).
Repeat Pulmonary Resections
Five patients (12%) underwent repeat pulmonary
resections.
Umehara et al.8 reported on a 77-year-old patient who
underwent total gastrectomy for stage IV (T4N2M0) adeno-
carcinoma. He subsequently had a left lower lobe segmen-
tectomy 12 months after gastrectomy and then had a left
upper lobe segmentectomy for pulmonary recurrence 23
months after gastrectomy. This patient was alive without
evidence of disease at 79 months postgastrectomy and 67
months after his first pulmonary metastasectomy. The second
patient in this series was a 58-year-old woman who under-
went a distal gastrectomy for stage IV (T4N3M0) adenocar-
cinoma. She had an initial recurrence in the liver 14 months
after gastrectomy and underwent liver resection, followed by
right upper and lower lung segmentectomies 36 months after
gastrectomy and then a repeat right lower segmentectomy 44
months after gastrectomy for pulmonary metastases. This
patient developed brain metastases and died of disease 65
months after gastrectomy and 29 months after her first pul-
monary resection.
Inoue et al.24 described a 68-year-old patient who
underwent a distal gastrectomy for stage I (T1N0M0) gastric
adenocarcinoma who underwent right upper lobectomy 96
months after gastrectomy and then underwent left upper and
lower lobe wedge resections at 108 months after gastrectomy.
This patient was alive without evidence of disease 180
months after gastrectomy and 84 months after initial pulmo-
nary metastasectomy.
Nakahashi et al.25 reported on a 59-year-old patient
who underwent total gastrectomy for stage IIIA (T3N1M0)
adenocarcinoma who experienced a recurrence and under-
TABLE 5. Prognostic Factors for Disease-Free Survival After
Pulmonary Resection
Feature Group Patients
Median
DFS (mo) p
Sex Male 23 36 0.303
Female 5 NR
Age 66.5 yr 14 36 0.108
66.5 yr 15 NR
Side of resection R 10 36 0.407
L 4 NR
Number of
pulmonary
lesions
1 24 36 0.398
1 5 48
Size of
pulmonary
lesions
23.5 mm 9 36 0.451
23.5 mm 8 NR
Type of
pulmonary
resection
Lobectomy 15 36 0.496
Other 10 NR
DFI from
gastrectomy
35 mo 15 48 0.427
35 mo 13 36
DFI from
gastrectomy
24 mo 11 36 0.848
24 mo 17 48
DFS, disease-free survival. DFI, disease-free interval.
TABLE 6. Prognostic Factors for Overall Survival After
Pulmonary Resection
Feature Group Patients
Median
OS (mo) p
Sex Male 24 29 0.396
Female 5 59
Age 66.5 yr 16 42 0.221
66.5 yr 14 NR
Number of pulmonary
lesions
1 26 45 0.901
1 5 42
Size of pulmonary
lesions
23.5 mm 8 NR 0.367
23.5 mm 9 65
Type of pulmonary
resection
Lobectomy 17 45 0.081
Other 10 NR
DFI from gastrectomy 35 mo 18 42 0.527
35 mo 13 45
DFI from gastrectomy 24 mo 14 19 0.119
24 mo 17 65
OS, overall survival. DFI, disease-free interval.
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went right middle lobectomy 24 months after gastrectomy.
During the next 18 months, the patient underwent right
adrenal and retroperitoneal metastasectomies in two separate
procedures. Sixty months after gastrectomy, the patient un-
derwent right upper lobe wedge resection for an additional
pulmonary metastasis and was alive without evidence of
disease 84 months after gastrectomy and 60 months after the
last pulmonary resection.
Nakayama et al.30 described a 59-year-old patient who
underwent a distal gastrectomy for stage II (T2N1) adeno-
carcinoma who then underwent right middle lobectomy for
two lesions 34 months after gastrectomy and then under-
went left lower lobectomy 82 months after gastrectomy.
He died of a cerebral infarct 99 months after gastrectomy
and 65 months after the last pulmonary resection with no
evidence of disease.
For patients with pulmonary recurrences after initial
resection, repeat metastasectomy was associated with signif-
icant increase in OS compared with those who did not
undergo repeat resection of their pulmonary recurrence (me-
dian OS: not yet reached versus 18 months, p  0.008).
When comparing these five patients who underwent repeat
resection with the rest of the patients who only underwent a
single resection, there was a trend toward increased OS
among those who underwent repeat resection, but this was
not statistically significant (median OS not yet reached versus
22 months, p  0.053).
Extrapulmonary Resections
Nine percent (4/43) of the patients had isolated
extrapulmonary metastases that were resected in addition
to pulmonary metastasectomy. Three patients had hepatic
metastases that were resected at 14 months, 38 months, and
an unspecified time after gastrectomy, and subsequently
underwent pulmonary resections at 36 months, 71 months,
and 16 months after gastrectomy, respectively. One patient
had a pulmonary metastasectomy at 24 months after gastrec-
tomy, followed by resection of a right adrenal metastasis at
30 months, resection of a retroperitoneal recurrence at 42
months, and a second pulmonary metastasectomy at 50
months after gastrectomy. There was no statistical difference
in OS after pulmonary metastasectomy among those patients
who underwent extrapulmonary metastasectomies compared
with those who did not (median OS: 29 months versus 23
months, p  0.635).
Follow-Up
Follow-up data were available for 91% (39/43) of the
patients at a median follow-up of 23 months (range: 3–180
months) (Table 7). Median DFS after pulmonary metastasec-
tomy was 36 months (range: 3–76 months) in the 33 patients
in which this information was available.
Thirty-eight percent (15/39) of patients had no recur-
rences at any site after their pulmonary resections, and an-
other 10% (4/39) had no recurrences after a resection of a
second pulmonary metastasis in a separate anatomic lobe.
Those patients without recurrence had a significantly longer
survival compared with those with further recurrences (me-
dian OS not yet reached versus 22 months, p  0.005).
Of the 56% (24/43) of patients with recurrences, 54%
(13/24) had recurrences in the lung after pulmonary resection.
One was in the same lobe, two were in the ipsilateral
hemithorax in a different lobe, three were in the contralateral
hemithorax, and seven were unspecified. Thirty-eight percent
(5/13) of these patients underwent repeat pulmonary resec-
tion, and all five had no further pulmonary or other recur-
rences, one of these patients developed a cerebral metastasis.
Seventeen percent (4/24) of the patients had intracranial
metastases, 13% (3/24) of the patients had bone metastases,
and 8% (2/24) had liver metastases after pulmonary metas-
tasectomy. Median time to recurrence after pulmonary resec-
tion was 12 months (6–48 months).
Follow-up for recurrences was measured by the authors
at the time of publication of the original article. At the end of
this period, 37% (16/43) patients were alive, and all were
without evidence of disease. During follow-up, 24 deaths
occurred with 63% (15/24) attributable to disease progres-
sion. Two patients had no evidence of disease at the time of
death from a cerebrovascular accident and pneumonia. Seven
patients had no listed cause of death. The status of three
patients was not reported.
Survival
Median survival after pulmonary metastasectomy was
29 months (range: 3–84 months) for the 36 patients in which
this information was available. The median survival from
gastrectomy was 65 months (range: 5–180 months) in the 38
patients in which this information was available. Kaplan-
Meier survival analyses are presented in Figures 1 and 2.
Thirty-one percent (11/36) of patients survived for
longer than 3 years after pulmonary resection, including 16%
(6/36) who survived for longer than 5 years, 6% (2/36) of
whom were alive at 76 and 84 months after metastasectomy
without evidence of disease with an OS of up to 15 years after
gastrectomy (Table 8). Nearly all these patients (5/6) were
alive and without any evidence of disease, and an additional
patient was deceased from other causes without evidence of
disease.
TABLE 7. Follow-Up
Median (mo) Range (mo)
Follow-up (n  39) 23 3–180
Time to recurrence (n  39) 11 5–48
n Percentage
Recurrence (n  39)
No recurrence 15 38
Recurrence 24 62
Brain 4 17
Bone 3 13
Liver 2 8
Pulmonary 13 54
Ipsilateral hemithorax 3 23
Contralateral hemithorax 3 23
Unspecified 7 54
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DISCUSSION
More than 60,000 patients with a history of gastric
cancer are currently alive in the United States.31 Given the
fact that up to one in seven patients will develop a pulmonary
recurrence and up to 1 in 16 patients will have isolated
pulmonary metastases, our study is potentially applicable to a
significant number of patients who have disease that is
amenable to surgical therapy.7–9 Patients with pulmonary
metastases from gastric cancer are considered nonsurgical
candidates, but those treated with chemotherapy alone have
poor survival that is measured on the order of several
months.10 We undertook an analysis of all published data of
patients who underwent pulmonary resections for MGC in an
attempt to identify potential patients who may benefit from an
aggressive surgical approach and to determine selection cri-
teria that can be used in a prospective study.
We report on 43 patients who underwent pulmonary
metastasectomy for MGC. The median OS of this group of
patients was 29 months (Figure 2B), and 5-year survival was
33% after pulmonary metastasectomy. Despite the obvious lim-
itations and biases, our data show that survival in a small
selected group of patients who underwent surgical removal of
pulmonary metastases from MGC can be potentially longer
compared with historical patients treated with standard chemo-
therapy.
The majority of published reports were case reports and
few small case series from larger tertiary centers, which is
understandable given the fact that resection of MGC from any
site is not common. Additionally, almost all reports were from
Japan, which is not surprising as this disease is more prevalent
in the East than in the West. The small number and the nature of
these publications indicate that a possible publication bias exists.
It is unreasonable to assume that “bad outcomes” for this
controversial procedure would be published.
Pathologic features of the primary tumors were evalu-
ated in an attempt to discern which patients might benefit
from metastasectomy. Eighty-five percent of primary tumors
invaded at least into the muscularis (T2) including 39% into
FIGURE 1. A, Disease-free survival after gastrectomy. B, Overall survival after gastrectomy.
FIGURE 2. A, Disease-free survival after pulmonary metastasectomy. B, Overall survival after pulmonary metastasectomy.
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and through the serosa (T3–T4). Sixty-five percent had nodal
involvement (N1–N3), and 47% of the patients presented in
advanced stage (stages III–IV). Nearly half of all tumors were
moderately or poorly differentiated, and several had evidence
of lymphatic and/or vascular invasion, all of which are
negative prognostic factors and could have contributed to the
development of metastases. These tumor characteristics are to
be expected given that our patient population was defined by
those who had pulmonary metastases. Not surprisingly, there
was a trend toward decreased DFS after gastrectomy among
patients with more advanced tumors.
More than 40% of patients with gastric cancer will
develop recurrences after curative gastrectomy. The majority
will recur within the first 2 years and nearly all within 4 years
of the initial operation.6 The patients in our report had a
median DFI of 35 months, which is longer than in historical
reports and suggests that there may be selection bias among
these patients who have a longer than average DFI after
gastrectomy. Approximately half of patients will recur dis-
tantly with metastasis to the liver 3 times as often as the
lung.6 As our patient population was selected from patients
who underwent pulmonary metastasectomy, not surprisingly,
nearly all patients (98%) recurred in the lung as the initial site
of metastatic disease. The next most common place for initial
recurrence was the liver; the two patients in our report had
DFI of 14 and 38 months, similar to that published in the
literature.
Nearly all patients in our study had metachronous
pulmonary metastases, the majority of which were unilateral,
single, and small. Because pulmonary resections of MGC are
not yet routine, it would be expected that only the most
favorable cases would be selected for resection as these
would be expected to lead to the best outcomes, and this
introduces another potential selection bias to this cohort.
Of note, nearly one third of patients were thought to
have primary lung cancer before resection of their pulmonary
metastasectomy. The frequency of primary lung adenocar-
cinoma in patients with existing gastric carcinoma has
been studied in the Japanese population in two studies,
which report a 0.5 to 1.7% incidence of primary lung
cancer in these patients.32,33 Although not common, the
possibility of primary lung cancer must be entertained in a
patient with pulmonary nodules who has a history of
resected gastric cancer. Modern immunohistochemistry
studies using special markers, such as thyroid transcription
factor 1 (TTF-1), can help make this distinction between
primary pulmonary adenocarcinoma and metastastic ade-
nocarcinoma from another site.
More than half of patients who were thought to have
primary lung cancer, or in which the definitive preoperative
diagnosis between primary lung cancer and MGC was not
clear, were operated in the modern era where TTF-1 and
other immunohistochemical techniques were used to defini-
tively diagnose these lesions as MGC and not primary lung
cancer. For the other patients who underwent resection before
the widespread use of TTF-1, it is possible that these lesions
could represent primary lung cancer; however, all clinico-
pathological data available at the time of resection andTA
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subsequent report in the literature identified these lesions as
MGC with the best certainty of available techniques.
A wide variety of operations were performed from
nonanatomic wedge resections to formal lobectomies. As the
primary objective for metastasectomy is complete removal
of tumor with grossly and microscopically negative mar-
gins, many options for pulmonary resection of MGC are
possible. Few of these studies reported morbidity, but as
pulmonary metastasectomies for other histologies have
become commonplace, it is expected that rates of compli-
cations after pulmonary resections for MGC would be
similar and acceptable.
In this report, five patients underwent repeat pulmonary
resections and three underwent hepatic resections before
pulmonary metastasectomy. Patients who undergo pulmonary
resection of colorectal metastases have a 30 to 45% 5-year
survival, and those who undergo repeat pulmonary metasta-
sectomies show similar long-term survivals to those with only
one resection,34–37 which was also seen among our five
patients who had repeat resections. In addition, pulmonary
resections after hepatic resections for colorectal metastases
are performed and can result in long-term survival with 60%
of the patients alive 3 years after pulmonary resection, similar
rates to those who underwent resection of either pulmonary or
hepatic metastases alone.37 In our report, patients who under-
went liver resection and subsequent pulmonary metastasec-
tomy for MGC had similar survival compared with those who
only had one pulmonary resection. It is not possible to draw
conclusions from these positive outcomes of few highly
selected patients. However, given the precedent for repeat
and multivisceral resections for metastatic colorectal cancer,
one can hypothesize that similar outcomes could be achieved
in MGC. This hypothesis should be explored in a scientific
manner in a randomized controlled trial.
Although surgery remains the mainstay in the treatment
of primary gastric cancer and remains the only curative modality
for this disease, the standard of care treatment for MGC is
systemic therapy. However, even with the modern addition of
perioperative chemotherapy and/or radiation therapy, the prog-
nosis of MGC has been only modestly improved. The best
reported results came from two phase II trials using 5-flu-
orouracil/leucovorin, oxaliplatin, and irinotecan (FOL-
FOXIRI) for patients with metastatic or recurrent gastric
adenocarcinoma. The median survival was 11.9 to 14.8
months and time to progression of 7.3 to 9.6 months; how-
ever, this regimen has yet to be tested in a randomized
fashion or in combination with surgical resections.38,39 In our
report, only one quarter of the patients received chemother-
apy in a neoadjuvant or adjuvant manner for their pulmo-
nary resection. This most likely reflects the fact that these
studies are from a wide range of time periods. As the
prospect of promising new chemotherapeutic regimens are
on the horizon, it is possible that in the future the combi-
nation of resection of MGC with chemotherapy may result
in longer, more durable responses than either modality
alone.
The median 5-year survival for pulmonary metastasec-
tomy, all histologies combined, is 43% for single lesions and
drops to 27% for four or more lesions.12 Among our patients,
of whom the majority had a single lesion, 5-year survival
after lung resection was 33%, leading to a median survival of
29 months from metastasectomy and a median survival of
more than 5 years from gastrectomy. Almost one quarter of
patients survived longer than 3 years including nearly 10%
who were alive longer than 5 years. These results are com-
parable with that which has been published previously for all
histologies combined, and although promising, is representa-
tive of a small group of highly selected patients. Neverthe-
less, these retrospective data are encouraging and suggest that
pulmonary metastasectomy may contribute to survival of
patients with MGC in a meaningful way. The hypothesis that
pulmonary metastasectomy for MGC prolong survival should
be tested in prospective randomized trial.
CONCLUSION
We report on a small and highly selected group of
patients where pulmonary metastasectomy for MGC re-
sulted in a median survival of 29 months. In contrast,
current standard of care options for these patients results in
limited survival measured in few months. Despite the
selection and publication biases and the retrospective na-
ture of our analysis, it is reasonable to consider pulmonary
metastasectomy for MGC in patients with single, small
lesions and a long DFI. To better address the question as to
whether systemic therapy in combination with resection of
oligometastatic disease prolong survival, we are currently
accruing patients for the Gastrectomy with Metastasec-
tomy Plus Systemic Chemotherapy Versus Systemic Che-
motherapy Alone (GYMSSA) trial, which will compare
gastric resection and metastasectomy plus FOLFOXIRI
compared with FOLFOXIRI alone for patients with metastatic
gastric cancer (ClinicalTrials.gov ID. NCT00941655).40
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